SCHEMBL19979749

SCHEMBL19979749

C=CCOC(=O)N1CCC[C@@H]1c1nc(CNC(=O)CCCCCCCCNC(=O)OC(C)(C)C)no1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.39
ALDH1A1 P00352 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
TSHR P16473 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HDAC8 Q9BY41 3/20 0.34
EPHA2 P29317 1/20 0.34
KDR P35968 1/20 0.34
EPHB4 P54760 1/20 0.34
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
PRCP P42785 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
DRD2 P14416 1/20 0.33
GBA1 P04062 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19979742 1.00 CYP3A4 (0.39) CYP3A4ALDH1A1MEN1KMT2ATSHR
SCHEMBL19979716 0.90 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ATSHRL3MBTL1
SCHEMBL19979715 0.90 ALDH1A1 (0.39) ALDH1A1MEN1KMT2ATSHRL3MBTL1
SCHEMBL19979810 0.86 DPP4 (0.35) CYP3A4ALDH1A1
SCHEMBL19979811 0.81 HCRTR1 (0.38) ALDH1A1TSHRPRCP
SCHEMBL19979812 0.81 HCRTR1 (0.38) ALDH1A1TSHRPRCP
SCHEMBL19975457 0.78 MAOA (0.39) ALDH1A1MEN1KMT2ATSHRL3MBTL1
SCHEMBL19979747 0.75 DPP4 (0.40) ALDH1A1TSHR
SCHEMBL19979809 0.73 CYP1A2 (0.38) ALDH1A1MEN1KMT2ATSHRL3MBTL1
SCHEMBL30147129 0.72 CYP1A2 (0.41) ALDH1A1MEN1KMT2ATSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018053302-A1 MACROCYCLIC COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF ENSEMBLE THERAPEUTICS CORPORATION (US) 2018-03-22 WO disclosed